Conference Description

June 3, 2006
Sheraton Boston Hotel
39 Dalton Street
Boston, Massachusetts
(617) 236-2000

Tell a friend about this conference

Download the brochure for this conference

CME Credits 6.0*

Nonrefundable registration fee: $0.

Target Audience: Rheumatologists, Nurse Practitioners, Physician Assistants, and Nurses in Rheumatology

Learning Objectives:
The intimate setting of this conference will maximize learning and discussion and will enable rheumatologists to learn first hand from thought leaders in their field. Among the proposed topics and objectives will be to:

1. describe the existing treatment options for the management of osteoporosis and a comparison of mechanisms of action and the administration of available bisphophonates
2. discuss the evidence supporting the safety and efficacy of intra-articular hyaluronan for the osteoarthritis treatment paradigm
3. discuss the integration of the biologic agents and the treatment of rheumatoid arthritis and other rheumatic diseases
4. review mechanisms including cytokines in inflammatory diseases
5. explain the safety and efficacy of new biologic agents in RA and B cell and T cell therapy
6. discuss new concepts in the management of anti-phospolipid syndrome

Agenda:

8:00-8:30		Registration and Continental Breakfast Welcome—Gerald S. Harris, MD
8:30-9:30		An update on Treatment Options for Osteoporosis Michael McClung, MD
9:30-10:30		Intra-articular Hyaluronan (IA-HA): Evidence, controversies, and product comparisons Philip A. Band, PhD
10:30-11:00		Morning Break—Tour Exhibits
11:00-12:00		Anti-Phospholipid Syndrome: New concepts in management Robert Lahita, MD
12:00-1:20		Luncheon
1:20-1:30		Conference Updates
1:30-2:30		An Update on the Use of Biologics in Other Rheumatic Disorders Alvin F. Wells, MD, PhD
2:30-3:30		Abatacept: A new biologic with a different mechanism Alvin F. Wells, MD, PhD
3:30-4:00		Afternoon Break—Tour Exhibits
4:00-5:00		New Biologics in RA and Update on B Cell Therapy Marc Cohen, MD
5:00		Closing Remarks—Gerald S. Harris, MD

Faculty:
Philip A. Band, Ph.D.
NYU School of Medicine
Department of Pharmacology
Department of Orthopedic Surgery

Marc Cohen, MD
Professor of Medicine
Mayo Medical School
Chairman of Division of Rheumatology>br> Mayo Clinic Jacksonville

Robert G. Lahita, MD, PhD
Vice-President and Chairman of Medicine
Jersey City Medical Center
Professor of Medicine, Mount Sinai Medical School

Michael R. McClung, MD
Associate Professor of Medicine
Oregon Health Sciences University
Director, Oregon Osteoporosis Center

Alvin F. Wells, MD, PhD
Clinical Assistant Professor
Rosalind Franklin University of Medicine and Sciences
Chicago, IL

Program Planning Committee:
Gerald S. Harris, MD
Charles Kahn, MD, FACP, FACR
Wayne G. Riskin, MD, FACP, FACR
Elaine Kahn, MSN, ARNP

Activity Director: Alan Goodstat, LCSW

*Continuing Education Information
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. UMMS is accredited by ACCME to provide continuing medical education for physicians. UMMS designates this continuing medical education activity for 6.0 credit hours in Category I toward the Physicians Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 7.2 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity.

In accordance with the Standards of the Accreditation Council for Continuing Medical Education (ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the policy of the University of Massachusetts Medical School to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented. Such disclosure will be made available on the day of the program.

This program was supported through educational grants from the following companies: Abbott Laboratories, Inc., Bristol-Myers Squibb, Centocor Inc., Genentech, Procter and Gamble, Sanofi-Aventis, and Smith & Nephew